Friday, May 29, 2015

Sangamo patent question mentioned in Cellectis/Pfizer merger article

From Biopharma-reporter:

Sangamo does not believe Cellectis' CRISPER patent applies to Sangamo ZFN technology.
 
Is Pfizer eyeing the CAR-T bandwagon? Rumours of €1.5bn takeover talks with Cellectis
By Gareth MacDonald+, 29-May-2015
CRISPR patent claimant Cellectis has declined to comment on rumours US drug giant Pfizer is in talks about a €1.5bn takeover.
 

 

Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)